Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Labradors and humans share the same obesity genes – new study
We led a study to find out how genes have such a significant influence on why humans (and dogs) become overweight. It was ...
Clinical Trials Arena on MSN5d
Palatin’s UC therapy prompts clinical remission in a third of patients
A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
In one dog breed, selection for utility may have selected for obesity
It turned out increased obesity risk in Labradors was linked to the same genes and mechanisms that cause obesity in humans.
Applied Clinical Trials Online19h
Palatin Announces Results from Phase II Obesity Study of MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
The combination met its primary endpoint of percent weight loss following an 8-week treatment period.
Medindia3d
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Palatin says BMT-801 Phase 2 obesity study met primary endpoint
Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...
The Pharma Letter2d
Palatin touts Phase II obesity study results
US drug developer Palatin Technologies (NYSE American: PTN) announced that its BMT-801 Phase II obesity co-administration ...
Yahoo Finance9d
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Morningstar6d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...